

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Hepalink**

**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9989)**

## **VOLUNTARY ANNOUNCEMENT INHIXA OBTAINS APPROVAL FROM NORTH MACEDONIA**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Compan** ”, together with its subsidiaries referred to as the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Inhixa, one of the Group’s leading drugs of enoxaparin sodium injection produced by Shenzhen Techdow Medicine Co., Ltd., a wholly-owned subsidiary of the Company, has been approved by the Agency For Medicines and Medical Devices (MALMED) of the Republic of North Macedonia for sales in the market.

### **DETAILS OF THE LICENSE**

- (I) Drug brand: Inhixa
- (II) Dosage form: Prefilled solution for injection
- (III) Strength: 20mg/0.2mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL
- (IV) Validity period of the license: until March 10, 2026

## **BENEFITS AND IMPACTS TO THE COMPANY**

Currently, the enoxaparin sodium injection products of the Group, have been approved in more than 50 countries for sales in the market and sold in 21 countries around the world. Meanwhile, the Group also can supply enoxaparin sodium injection to its customers in 15 other countries. The Board believes that those good feedbacks of sales and safety data in overseas markets over the past three years has enabled the Group to obtain more market share, and the Board expects that this registration approval will further accelerate the global layout advancement of the Company's finished dose pharmaceutical business.

Announcement is hereby given.

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
April 13, 2021

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xuan; the non-executive director of the Company is Mr. Bu Haihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*